CalciMedica, Inc.

Stage 4 · Declining · week 10

As of Oct 22, 2026, CalciMedica is in Stage 4, the downtrend phase, now in week 10 (since Aug 19, 2026). It closed at $1.15, 96.6% below its 52-week high and below its 200-day average, which is falling.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. More about the company

$1.15

+0.00% today

$7.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CALC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S? 32w

S4 39w

S2 15w

S1 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 32w → S2 1w → S3 4w → S2 9w → S3 6w → S4 5w → S1 1w → S4 39w → S1 5w → S2 9w → S3 1w → S2 15w → S3 4w → S4 9w → S1 14w → S4 9w current

Total tracked: 165 weeks across 16 stage runs.

CALC among Biotechnology520th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…520	CALCCalciMedica, Inc.	Stage 4 · wk 10	6	−35.8%

vs 52W High

-96.6%

$1.02 lo$33.70 hi

96.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 10

1w13w26w

Week 10, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-76.1%

200 DMA: $4.82 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.39x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-35.8%

-69.7%

-60.3%

YTD

-96.6%

-92.7%

Scan Membership

Breakout Watch

Latest: 2024-05-10

2 appearances in last 60 days. First seen: 2024-04-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 10 · Vol 1.39x

2026-10-21S4

Wk 9 · Vol 1.87x

2026-10-20S4

Wk 9 · Vol 0.55x

2026-10-19S4

Wk 9 · Vol 0.23x

2026-10-16S4

Wk 9 · Vol 0.17x

2026-10-15S4

Wk 9 · Vol 0.29x

2026-10-14S4

Wk 8 · Vol 0.52x

2026-10-13S4

Wk 8 · Vol 1.22x

2026-10-12S4

Wk 8 · Vol 0.92x

2026-10-09S4

Wk 8 · Vol 1.01x

2026-10-08S4

Wk 8 · Vol 2.84x

2026-10-07S4

Wk 7 · Vol 0.10x

Moving averages & range

50 DMA

$1.97

200 DMA

$4.82

52W High

$33.70

52W Low

$1.02

5D Low

$1.02

Resistance levels (recent highs)

20d High

$1.75

60d High

$5.00

120d High

$5.30

250d High

$33.70

Next resistance

+52.2%

to 20d High

ROE

-365.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

CalciMedica: quick answers

What stage is CalciMedica in?

As of Oct 22, 2026, CalciMedica (CALC) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 19, 2026 and is in week 10. What the four stages mean

Is CalciMedica in an uptrend?

No. CalciMedica is in a Stage 4 downtrend. It trades 76.1% below its 200-day average, which is falling.

How far is CalciMedica from its 52-week high?

CalciMedica closed at $1.15 on Oct 22, 2026, 96.6% below its 52-week high of $33.70. Its 52-week low is $1.02.

How has CalciMedica performed over the past year?

As of Oct 22, 2026, CalciMedica is down 92.7% over the past year and down 96.6% so far in 2026.

Which sector and industry is CalciMedica in?

CalciMedica is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.